DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma by Galbán, Stefanie et al.
DW-MRI as a Biomarker to Compare Therapeutic
Outcomes in Radiotherapy Regimens Incorporating
Temozolomide or Gemcitabine in Glioblastoma
Stefanie Galba ´n
1, Benjamin Lemasson
2, Terence M. Williams
1, Fei Li
2, Kevin A. Heist
2,
Timothy D. Johnson
3, Judith S. Leopold
1, Thomas L. Chenevert
1, Theodore S. Lawrence
2,
Alnawaz Rehemtulla
1,2, Tom Mikkelsen
4, Eric C. Holland
5, Craig J. Galba ´n
2, Brian D. Ross
2*
1Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America, 2Department of Radiology, University of Michigan, Ann
Arbor, Michigan, United States of America, 3Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, United States of America, 4Department of
Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan, United States of America, 5Departments of Cancer Biology and Genetics and
Neurosurgery, and Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
Abstract
The effectiveness of the radiosensitizer gemcitabine (GEM) was evaluated in a mouse glioma along with the imaging
biomarker diffusion-weighted magnetic resonance imaging (DW-MRI) for early detection of treatment effects. A genetically
engineered murine GBM model [Ink4a-Arf
2/2 Pten
loxP/loxP/Ntv-a RCAS/PDGF(+)/Cre(+)] was treated with gemcitabine (GEM),
temozolomide (TMZ) +/2 ionizing radiation (IR). Therapeutic efficacy was quantified by contrast-enhanced MRI and DW-MRI
for growth rate and tumor cellularity, respectively. Mice treated with GEM, TMZ and radiation showed a significant reduction
in growth rates as early as three days post-treatment initiation. Both combination treatments (GEM/IR and TMZ/IR) resulted
in improved survival over single therapies. Tumor diffusion values increased prior to detectable changes in tumor volume
growth rates following administration of therapies. Concomitant GEM/IR and TMZ/IR was active and well tolerated in this
GBM model and similarly prolonged median survival of tumor bearing mice. DW-MRI provided early changes to
radiosensitization treatment warranting evaluation of this imaging biomarker in clinical trials.
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Introduction
Approximately 50% of all patients diagnosed with brain tumors
have the most malignant form, glioblastoma multiforme (GBM).
Despite aggressive treatments that consist primarily of surgical
resection followed by chemoradiotherapy the prognosis remains
poor with a median survival of 14 months from diagnosis [1]. The
standard of care for glioma patients continues to be concurrent
temozolomide and radiotherapy which provides a modest
improvement in survival over radiation alone [2]. With a better
understanding of the genetic make-up of GBM [3], molecular and
genetic profiling is being investigated for biomarkers to predict
treatment efficacy [4]. One prognostic factor identified as a
reliable biomarker for GBM sensitivity to temozolomide is the
methylation status of O
6-methylguanine-methyl-transferase
(MGMT) [5]. In a multisite trial, patients with active MGMT,a n
enzyme responsible for DNA repair, were found to receive little
benefit from treatment by alkylating agents (i.e. Temozolomide)
[6,7]. Thus new chemotherapeutic drugs are being investigated in
the clinic for patients who will unlikely benefit from temozolomide.
In this regard Gemcitabine is considered a possible candidate due
to its different mechanism of action as it is known to irreversibly
inhibit the production of nucleic acids. Emerging results have
shown initial promise for use of Gemcitabine as an alternative
radiosensitizer for tumors identified as MGMT active (unmethy-
lated) [8,9].
Recent advances to better understand and treat GBMs have
also been made by examining alterations in gene amplifications or
gene expression by several groups. The Cancer Genome atlas
network (TCGA) has cataloged recurrent genomic abnormalities
in GBM and has classified GBM based on abnormalities in the
genes encoding PDGFRA, IDH1, EGFR and NF1 GBM into four
subgroups: the proneural, neural, classical and mesenchymal,
respectively [3]. The responses to aggressive therapy have been
found to differ by subtype thus this new classification scheme will
likely provide a future framework for targeted therapy selection.
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beneficial at identifying treatment options most likely to succeed
[4], they are subject to tumor heterogeneity and once therapy has
begun, assessment of response is based primarily on changes in
contrast-enhancing tumor volume. The MacDonald criteria for
assessing tumor response to treatment are predominantly based on
monitoring changes in summed tumor area as measured by CT or
MRI 10–12 weeks post-treatment initiation [10]. This approach
has been the mainstay of clinical management of glioma patients
for the past 20 years. In 2010, the Response Assessment in Neuro-
Oncology (RANO) Working Group set new guidelines for
assessing therapeutic response that address some of the deficiencies
in the MacDonald criteria [11]. While an improvement over its
predecessor, RANO continues to assess tumor response by
anatomical MRI following the completion of therapy. Thus, while
a significant need for improved therapies for the treatment of
GBM patients with active MGMT status remains, there also exists
the need for development of additional biomarkers of treatment
response which could be used to provide an early indication of
therapeutic outcome.
Quantitative imaging techniques, derived from positron emis-
sion tomography or MRI, are being investigated extensively as
biomarkers of tumor response to therapy [12,13,14,15]. The
rationale for employing these methodologies is their ability to
quantify physiological alterations within the tumor during therapy
which may serve as surrogates for overall survival. Diffusion-
weighted (DW-) MRI has been studied extensively for its
prognostic capabilities in identifying patients responsive to
treatment [16,17]. Treatment-induced loss of tumor cellularity
leads to an increase in water mobility that is detectable by DW-
MRI since alterations in tumor tissue architecture (such as cell
membrane, extracellular matrix and organelles) which restrict the
thermal driven displacement of water molecules are reduced [18].
First demonstrated as a biomarker of therapeutic response in 9L
glioma-bearing rats treated with a chemotherapeutic (BCNU)
[19,20], DW-MRI has been investigated in clinical studies by
many researchers over a variety of tumor types [21,22,23,24].
Due to the complex, and sometime unpredictable, interaction
between novel therapeutic agents and glioma biology, various
mouse models of GBM have been developed and are currently
available to the research community [25,26,27]. One animal
model wherein key signaling pathways can be turned on and off to
investigate targeted therapy is based on the RCAS-tva technology
[27,28]. In an effort to represent the proneural, PDGF driven
subtype of human GBM, this mouse model is also PDGF driven
where PTEN is deleted in nestin expressing cells in an ink4/arf
deficient background [29,30,31,32]. This PDGF driven highly
proliferative mouse model has been found to exhibit pathological
features similar to the human GBM subtype [30,33,34]. Herein we
sought to investigate the effectiveness of DW-MRI as a surrogate
biomarker of treatment response in this animal model that mimics
the proneural GBM class of tumors. Since clinical studies have
validated the effectiveness of DW-MRI as an imaging biomarker
in glioma patients treated with the temozolomide and radiother-
apy [35,36,37,38], it is important to evaluate this biomarker in a
preclinical setting exploring the efficacy of promising alternative
therapeutic agents (i.e. gemcitabine).
The PDGF-driven genetically engineered model has been
shown to express high levels of MGMT in the stem-like GBM
cells [39] while the bulk tumor had about a 3-fold lower level of
MGMT expression. The lack of epigenetic silencing of the MGMT
gene in a subset of GBM patients allows for more efficient repair of
DNA damage induced by alkylation following treatment with
temozolomide chemoradiotherapy. Therefore, there is a clinical
need to not only improve radiosensitization of GBM’s but also to
identify predictive imaging biomarkers of response. Here we
demonstrate that gemcitabine, which has been shown to pass the
blood-tumor barrier in GBM patients [40], is an excellent
radiosensitizer for the proneural PDGF driven GBM subtype,
which is in accordance with other pre-clinical data of U251
human glioblastoma cell line treated with GEM/IR [41]. These
results support the clinical exploration of gemcitabine in
combination with IR as an alternative treatment for GBM
patients who fail to respond to TMZ/IR, and whose tumors fall
in the proneural PDGF-driven classification.
Results
Study 1: Evaluation of Combination TMZ/IR in reducing
tumor burden in PDGF-driven mouse GBM
As presented in Figure 1, single therapies were significantly
more efficacious than vehicle. Median survival was 2 and 3 fold
greater for TMZ (10 days (d): 95% confidence interval (CI) 5.8–
14.1 d; p,0.0001) and IR (16 d: 14.2–17.8 d; p,0.0001),
respectively, than controls (5 d: 4.6–5.4 d). No significant
differences in survival were observed between single agent treated
groups (p=0.08). By contrast, combination of TMZ and IR was
significantly more efficacious than all other treatment groups
(p,0.0001) with a median survival of 23 days (CI=21.7–24.3 d)
and was well tolerated in this GBM model. The body weight loss
during treatment never exceeded 10% for all treatment arms. The
endpoint of survival was defined as the time point in which the
animal had to be removed from the study due to poor health
caused by excessive tumor burden.
The percent change in tumor volume and mean ADC values
are presented in Figure 2 for each treatment group over the first
week post-treatment initiation. Animals treated with vehicle
generated the highest change in tumor volume (doubling time of
260.1 days) with negligible percent change in tumor ADC
(Figure 2A). In contrast, single agent therapy using IR (Figure 2B)
or temozolomide (Figure 2C) and combination therapies
(Figure 2D) resulted in a lower volume percent tumor volume
change such that significant differences from control were
observed as early as two days post-treatment initiation. Although
tumor doubling times were extended for single agent therapies (IR:
663 days and TMZ: 560.4 days) over controls, only chemor-
adiotherapy was found to completely control tumor growth with
tumor volumes at the end of therapy (i.e. 2 week of treatment) at
pre-treatment levels that were 3–6 times smaller than tumors
treated with single agents (data not shown). Similarities in efficacy
for TMZ and IR were observed, nevertheless IR was found to
have a more immediate effect on the tumor with ADC percent
changes significantly higher than controls by day 1 (Fig. 2B). This
suggests substantial cell kill early in IR therapy. ADC values were
found to increase steadily throughout TMZ treatment signifying
some cell kill, which explains the slow but steady increase in tumor
volume (Fig. 2C). A steady increase and decrease was observed for
tumor volume and ADC, respectively, following the day 3 of
treatment in the IR group suggesting recovery of the tumor from
therapy. This was not observed in TMZ-treated animals possibly
attributable to residual TMZ in the blood stream. The
combination of TMZ and IR was the only therapy capable of
controlling tumor growth that even resulted in a drop in tumor
volume below pre-treatment values. Following one full cycle of
treatment (day 4) chemoradiation resulted in significantly higher
changes in tumor mean ADC (Fig. 2D) compared to other
treatment groups with mean ADC values due to TMZ+IR
treatment increased from baseline by 16% on day 4.
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sections from representative animals in each treatment group.
Two days following the end of the first cycle of vehicle treatment
(day 7) low ADC values were observed. These values correlate
with negligible caspase-3 staining, a marker for cell apoptosis. In
contrast, animals treated with IR, TMZ alone or TMZ/IR
generated elevated values in ADC above control and showed
positive stained apoptotic cells. Therapeutic response was very
spatially heterogeneous in treated animals, partly attributed to
spontaneous necrosis and pooling of blood as depicted as
hypointense and low ADC (,0.4 mm
2/s) regions in the CE-T1-
weighted images and ADC maps, respectively. The lack of
cellularity differences as determined by H&E between groups is
attributed to the aggressive nature of this glioma model. As
determined from the growth pattern of tumors in vehicle treated
animals, the mean doubling time was found to be 4263 hours.
Induction of cell death in the various treatment groups was
further evaluated by conventional western blotting for cleaved
caspase-3. As depicted in Figure 3B, tumor tissue at Day two post-
treatment initiation from all experimental groups were evaluated
for the cleavage of pro-caspase-3 into the two isoforms (17 and
19 kDa). As predicted by DW-MRI elevated levels of the two
cleaved caspase-3 forms were detected predominantly in the tumor
tissues excised from animals treated with the combination of TMZ
and IR indicating an increased level of apoptosis.
Study 2: Evaluation of Combination GEM/IR in reducing
tumor burden in PDGF-driven mouse GBM
Single agent treatment with GEM resulted in similar survival
plots (Fig. 4) to those observed in Study 1. Animals treated with IR
or GEM lived significantly longer than control animals with
median survival of 15 days for both (IR, CI: 13.5–16.5 d and
GEM, CI: 12.4–17.6 d). Combining these therapies improved the
median survival to 21 days (CI: 20.1–21.9 d), which was
significantly longer than all of the other treatment groups in this
study (p,0.05) and was well tolerated. The body weight loss
during treatment never exceeded 10% for all treatment arms. The
endpoint of survival was defined as the time point in which the
Figure 1. Kaplan-Meier survival plots are presented for each therapy in Study 1. (A) Schematic of treatment schedule for study 1. Animals
were randomized into four groups: control [DMSO/saline], irradiation (IR) [DMSO/saline followed by 1 Gy with 3 hour lag in between treatments],
TMZ [50 mg/kg in DMSO/saline] and TMZ+IR [50 mg/kg in DMSO/saline followed by 1 Gy with a 3 hour lag time between treatments]. All treatments
were administered five days a week for two weeks.(B) Treatment groups are Controls, irradiation (IR), temozolomide (TMZ) and combination
temozolomide and irradiation (TMZ+IR).
doi:10.1371/journal.pone.0035857.g001
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caused by excessive tumor burden.
Control and IR groups generated profiles in percent change in
tumor volume and mean ADC over the first 7 days similar to that
observed in Study 1, though the vehicle was different. As seen in
Figure 5, all treatment groups had significantly lower percent
change in tumor volumes from control (doubling time of 260.1
days) at day 1 post-treatment initiation. As in Study 1, single agent
therapies extended tumor doubling times (761 days for both IR
and GEM) with chemoradiotherapy completely controlling tumor
growth during the 2 week cycle. Again, tumor volumes treated
with chemoradiation were 4–6 times smaller than their single
agent counterparts. IR animals produced ADC percent change
values significantly higher than controls by day 4. What is striking
about the use of GEM is that although the tumor volume plots
behaved similarly to TMZ treatment, the ADC response was
almost immediate with over a 10% increase for both single and
combination GEM therapies by 24 hours, Figure 5C and
Figure 5D, respectively which were significantly higher than
controls. In fact, the peak in ADC at days 1, 4 and 7 corresponded
to GEM doses delivered 24 hours previously (Fig. 5C, 5D). This
sharp increase in ADC suggests massive cell kill in the tumor
following the GEM dose. By 48 hours, ADC values immediately
decreased towards pre-treatment values, indicating the aggressive-
ness of this glioma model and its ability to recover from GEM
treatment. Inclusion of IR with GEM had a significant effect on
the tumors as observed not only in their tumor volume
measurements but also in their mean ADC values. Tumor mean
ADC values were found to increase by up to 22% from baseline
for GEM+IR treatment group by day 4 post-treatment initiation,
which was significantly higher than all other therapies (p,0.05).
The representative MR images in Figure 6A show elevated
ADC values in animals treated with GEM either alone or in
combination. These elevated ADC values are a result of the third
dose of GEM, which was administered on day 6. Although tumor
cellularity between treatment groups as assessed by visual
inspection of histology was similar, caspase-3 staining was slightly
more pronounced in GEM treated animals as compared to control
and IR groups.
Similar to Study 1, proteins from tumor tissues of all treatment
groups were harvested and assessed for the induction of apoptosis
by cleaved caspase-3 staining. As depicted in Figure 6B the
combination of gemcitabine with radiotherapy resulted in an
increase of cleaved caspase-3 staining compared to vehicle, GEM,
or IR treated animals.
Discussion
Evaluation of novel or existing therapies or treatment
paradigms for GBM can be facilitated by the use of pre-clinical
mouse models [42]. Herein we utilized an existing PDGF-driven
GBM mouse model wherein known dominant signaling pathways
are deregulated, thereby recapitulating the human disease [30,32].
Specifically, we wanted to evaluate an existing prognostic DW-
MRI biomarker (ADC) and demonstrate its utility in predicting
treatment outcome in a pre-clinical model, which would allow for
Figure 2. Plots of the percent change in tumor volume and normalized ADC (ADC) for each of the treatment groups in Study 1.
Presented are treatment groups (A) Control, (B) irradiation (IR), (C) temozolomide (TMZ) and (D) combination temozolomide and irradiation (TMZ+IR).
Data is presented over the first week of the study as the mean 6 SEM.
doi:10.1371/journal.pone.0035857.g002
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standard care for GBM patients today is temozolomide in
combination with radiotherapy [43]. The addition of temozolo-
mide to radiation alone in the treatment paradigm for GBM
patients resulted in a median survival benefit of 2.5 months thus
gaining acceptance as standard of care [2]. However compared to
other cytotoxic agents, temozolomide is a relatively poor
radiosensitizer and the results of a recent multisite study have
demonstrated that patients with unmethylated MGMT gene
promoter will benefit relatively little from this treatment [5,6,8].
Methylation of the MGMT promoter occurs in about 30 to 60% of
glioblastoma patients which is associated with favorable patient
outcome using alkylating agents [44,45]. This and other findings
have prompted the pre-clinical investigation and several clinical
trials to consider combination therapy of gemcitabine with
radiation in GBMs [9,40]. Gemcitabine, unlike temozolomide is
an excellent radiosensitizer as demonstrated by numerous studies
both in vitro and an in vivo [8,40,44] and exerts its antitumor effects
independent of MGMT status [9]. Gemcitabine’s potential as a
radiosensitizer was first demonstrated in the human glioblastoma
cells U251, which were radiosensitized by a nontoxic concentra-
tion of 10 nM [41]. In a different study ectopic human
deoxycytidine kinase gene expression was shown to enhance the
cytotoxic and radiosensitizing effect of gemcitabine on experi-
mental C6 and U373 intracranial gliomas [35]. Only a few clinical
studies have thus far been performed with gemcitabine in the
GBM patient population [9,40,44]. In a phase 0 study,
gemcitabine was found to cross the blood-tumor barrier [40]
Figure 3. MR, histological images and western blots are presented from representative animals in Study 1 treatment groups. (A) MRI
data consists of anatomical contrast-enhancing T1-weighted images and ADC maps. Histological stains provide information on tumor cellularity
(H&E) and apoptosis (cleaved Caspase-3). All data were acquired at day 7 post-treatment initiation. (B) Representative western blot for the detection
of cleaved Caspase 3 in tumor tissue from all treatment groups. B-Actin was used as a loading control to ensure proper loading of the protein
samples. The tumor tissue from all groups was acquired at day 2 post-treatment initiation.
doi:10.1371/journal.pone.0035857.g003
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determined to be a tolerable and safe treatment for newly
diagnosed GBM patients yet the GEM schedule used did not
confer a survival benefit [46]. However, promising results were
obtained in a phase I dose finding study with a fixed dose-rate of
GEM (175 mg/m
2/weekly) [47].
The current study consisted of two Studies wherein DW-MRI
was tested as a prognostic biomarker. Study 1 evaluated DW-MRI
as a response metric to the glioma model treated with
temozolomide and radiation therapy, the standard of care.
Performing the same analysis as in Study 1, Study 2 evaluated
DW-MRI using gemcitabine, a promising alternative therapy,
concurrent with radiotherapy. As designed, single therapies
resulted in improved survival over control. For both Study 1
and Study 2, IR treated animals exhibited a sharp increase in
ADC suggesting a sufficient drop in tumor cellularity resulting
from cell kill. Following treatment (day 4) ADC values regressed
back towards baseline. TMZ treated animals did not generate the
profile in ADC observed for IR. In fact, ADC values remained
elevated even after treatment had ceased on day 4. GEM yielded
the most unique ADC profile. The response of the tumor to the
drug as determined by ADC was almost immediate. It is highly
likely that the peak ADC value was not obtained due to the
insufficient temporal resolution for such an aggressive tumor.
When combining therapies the ADC profile was found to generate
changes in values significantly higher than what was observed for
single agent treatments. In the case of Study 1, the profile of ADC
over time was similar between IR and TMZ+IR therapies.
Contrary to Study 1, the effect of GEM was clearly evident in the
ADC profile for both GEM and GEM+IR therapies.
The results of this study showed that changes in ADC were
sensitive to tumor response to treatment but were unable to
definitively predict the efficacy between treatment groups. As
validated by the rapid change in ADC following treatment and the
apparent lack of cellularity differences between groups by
histology, the aggressiveness of this particular tumor model likely
contributes to an attenuated ADC measurement. As observed in
the contrast-enhancing MR images in Figures 3 and 6, there was a
Figure 4. Treatment schedule and Kaplan-Meier survival plots are presented for each therapy in Study 2. (A) Treatment schedule
schematic for Study 2. Animals were randomized into four groups: control, IR, GEM and GEM+IR. Animals of the control group received vehicle 2 days
a week for 2 weeks. Animals in the IR group received 1 Gy for 5 days as week with a two day break between treatment blocks for 2 weeks. The GEM
group received 10 mg/kg GEM in saline i.p., and GEM+IR received GEM i.p. followed by 1 Gy with a 3 hour lag time between treatments. Control
vehicle and GEM administration occurred every third day for a total of four doses. Arrows indicate the day of treatment. (B) Treatment groups are
Controls, irradiation (IR), gemcitabine (GEM) and combination gemcitabine and irradiation (GEM+IR).
doi:10.1371/journal.pone.0035857.g004
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added additional challenges when using this model. These regions
were partly due to spontaneous necrosis and blood pooling and
had to be filtered prior to ADC analysis as these regions are
difficult to accurately quantify by DW-MRI due to the lack of
signal. In addition, this glioma model was found to be highly
sensitive to chemoradiotherapy, which required daily monitoring
of tumor volume and ADC measurements to get an accurate
profile of tumor response. When treating with combination
therapy, tumor volumes decreased rapidly and reached volumes
below the pre-treatment value. This made it difficult to achieve
accurate tumor volume and ADC values. Finally, tumor
delineation was performed by contouring on the enhancing rim
of the tumor. Additional MR modalities (i.e. T2 weighted and
FLAIR) were tested but none provided the needed contrast to
identify the tumor margins. As a consequence, the contrast-
enhancing rim may have extended into healthy brain tissue
introducing error into tumor volume measurements.
Diffusion MRI changes are usually indicative of changes in
tumor cellularity caused by cell death. Thus tumor tissue from all
treatment groups was evaluated by histology and western blotting.
In general, positive caspase-3 staining was identified in all
chemotherapeutic treatment groups, yet was most pronounced
in the combination groups. While large differences in tumor
volume were observed between groups at day 7 post-treatment
initiation, at the same time point there was an apparent lack of
cellularity differences between the groups as analyzed by H&E
staining. A possible explanation of this discrepancy could be the
aggressive nature and high proliferation rate of this particular
glioma model which would allow the tumor cellularity to recover
quickly following treatment. This would be in agreement to the
sudden drop in ADC values observed at day 7 following IR and
24 hours after each successive GEM dose.
As defined by Verhaak et al.’s classification [3] the major
features of the proneural GBM class apart from PDGFRA
alterations were point mutations in IDH1. The mouse model
used in this study was IDH1 and IDH2 wild-type, thus our
findings revealed that combining gemcitabine with radiation was
efficacious in reducing tumor burden and prolonging median
survival when compared to radiation or gemcitabine alone in this
class of GBM. Therefore, this study demonstrated the efficacy of
combining gemcitabine with radiotherapy as an alternative
treatment strategy for GBMs of the proneural subtype and the
utility of DW-MRI as a prognostic imaging biomarker shown to be
capable of early quantification of treatment outcome. The design
of future GBM clinical trials should include the use of the DW-
MRI biomarker in order to provide additional metrics for
quantitative and spatial assessment of tumor responsiveness.
Materials and Methods
Cell culture
DF-1 cells were purchased from ATCC. Cells were grown at
39uC according to ATCC instructions. RCAS-PDGF-B-HA or
RCAS-Cre were a gift from E. Holland and have been described
previously [29,30,36,38]. Transfections with RCAS-PDGF-B-HA
Figure 5. Plots of the percent change in tumor volume and normalized ADC (ADC) for each of the treatment groups in Study 2.
Presented are treatment groups (A) Control, (B) irradiation (IR), (C) gemcitabine (GEM) and (D) combination gemcitabine and irradiation (GEM+IR).
Data is presented over the first week of the study as the mean 6 SEM.
doi:10.1371/journal.pone.0035857.g005
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according to manufacturer instructions (Roche Roche Applied
Science, Indianapolis). Expression of PDGF and Cre was
confirmed by western blotting (HA-HRP antibody (Sigma, St.
Louis, MO and Cre (Covance Inc., USA).
Intracranial inoculation
All animal work was conducted according to University of
Michigan Laboratory of Animal Management Guidelines under
UCUCA Protocol#09583.The University of Michigan Laborato-
ry Animal Committee approved of the use of animals for this
study. Generation of the Nestin-tv-a, ink4a-Arf
2/2/, Pten
loxp/loxp
mouse line s have previously been described [29,30,36,37,38]..
The animals were originally acquired from E. Holland and inbred
at the University of Michigan ULAM facility. 4–6 week old
transgenic mice (Nestin-tv-a, ink4a-Arf
2/2/, Pten
loxp/loxp) were
anesthetized with ketamine (0.1 mg/kg) and xylazine (0.02 mg/
kg). One microliter of 8610
4 cell mixture containing an equal
amount of RCAS-PDGF-B and RCAS-Cre transfected DF1 cells
was delivered using a 30-gauge needle attached to a Hamilton
syringe and stereotactic fixation device (Stoelting, Wood Dale, IL).
Cells were injected to the right frontal cortex: coordinates bregma
1.5 mm, Lat 0.5 mm, and a depth 1.5 mm. Mice were monitored
carefully and sacrificed when they displayed lethargy or head tilt
Figure 6. MR and histological images and western blots are presented from representative animals in Study 2 treatment groups. (A)
MRI data consists of anatomical contrast-enhancing T1-weighted images and ADC maps. Histological stains provide information on tumor cellularity
(H&E) and apoptosis (caspase-3). All data were acquired at day 7 post-treatment initiation. (B) Tumor tissue from animals left untreated or treated
with GEM, IR and GEM+IR at day two post-treatment initiation was assessed for cleaved Caspase 3. Western blot of representative animal tissue is
shown and proper loading of protein samples was ensured by probing for Gapdh.
doi:10.1371/journal.pone.0035857.g006
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guidelines were used to assess the degree of morbidity by following
endstage-illnesse scoring procedure and a tumor burden scoring
system. Animals remained in the study until they became
moribund. If animals displayed severe signs of morbididty, or a
moribund state animals were were graded by appearance, natural
behavior, provoked behavior, and body condition score.
Treatment
Following intracranial inoculation tumor volumes were moni-
tored and calculated by contrast-enhanced T1-weighted MRI
imaging as described below. Once tumor volume reached 20–
40 mm
3 pre-treatment MRI images were acquired and treatment
was initiated. The animals were randomized into 4 different
treatment groups per study (n$8 per group). Temozolomide
(TMZ) was prepared in a mixture of 60% dimethyl sulfoxide
(DMSO) and 40% saline. Gemcitabine (GEM) was prepared by
dissolving in saline. Solutions were prepared fresh and adminis-
tered within one hour of preparation. Therapeutic agents were
purchased from LKT laboratories, Inc., St. Paul, MN, USA.
For cranial irradiation (IR), mice were restrained in a small
plastic restraining device and the area to be irradiated (whole
brain) was exposed while the rest of the body was shielded with
lead to decrease radiation toxicity to normal tissues.
Based on preliminary dose finding experiments, we identified
GEM (10 mg/kg), TMZ (50 mg/kg) and 1 Gy IR as minimally
efficacious doses at multiple doses instead of one weekly dose and
the schedule combination was chosen for our GBM mouse model
to yield enhanced survival in combination with a radiosensitizer
such as GEM.
Study 1. Animals selected for this study were randomized into
four groups: control, irradiation (IR), TMZ and TMZ+IR.
Treatments were administered as followed: Control animals
received an intraperitoneal injection of DMSO/saline, the IR
group received DMSO/saline i.p. followed by 1 Gy with 3 hour
lag time between treatments, the TMZ group received 50 mg/kg
TMZ in DMSO/saline i.p., and the TMZ+IR group received
TMZ i.p. followed by 1 Gy with a 3 hour lag time between
treatments. All treatments were administered five days a week for
two weeks.
Study 2. Animals selected for this study were randomized into
four groups: control, IR, GEM and GEM+IR. Treatments were
administered as followed: Control animals received an
intraperitoneal injection of saline, the IR group received saline
i.p. followed by 1 Gy with 3 hour lag time between treatments, the
GEM group received 10 mg/kg GEM in saline i.p., and GEM+IR
received GEM i.p. followed by 1 Gy with a 3 hour lag time
between treatments. Control vehicle and GEM administration
occurred every third day for a total of four doses. IR was
administered as described in Study 1.
MRI Scans
MRI scans were performed on a 9.4T, 16 cm horizontal bore
(Agilent Technologies, Inc., Santa Clara, CA) Direct Drive system
with a mouse head quadrature volume coil or mouse surface
receive coil (m2m Imaging, Corp., Cleveland, OH) actively
decoupled to a whole-body volume transmit coil (Rapid MR
International, LLC., Columbus, OH). Throughout the MRI
experiments, animals were anesthetized with 1–2% isofluorane/
air mixture, and body temperature was maintained using a heated
air system (Air-Therm Heather, World Precision Instruments,
Sarasota, FL). MR images were acquired prior to treatment
initiation, daily during the first seven days for Study 1 and 3 days
for Study 2 and every other day until the animals were sacrificed
or became moribund.
MRI experiments consisted of two imaging sequences to
measure tumor volume and tumor apparent diffusion coefficient
(ADC). Delineation of tumor from healthy brain tissue was
determined using a contrast-enhanced T1-weighted spin-echo
images with the following parameters: Repetition time (TR)/echo
time (TE)=510/15 ms, field of view (FOV)=20620 mm
2, matrix
size=1286128, slice thickness=0.5 mm, 25 slices and 2 averages.
Total acquisition time was 2 minutes and 12 seconds. Contrast-
enhancement was performed by i.p. administration of 50 mlo f
0.5 M gadolinium-DTPA (Magnevist, Bayer Healthcare Pharma-
ceuticals, Wayne, N.J) 5 minutes prior to image data acquisition.
Tumor ADC maps were obtained from a diffusion-weighted spin-
echo sequence, equipped with a navigator echo for motion
correction and gradient waveforms sensitive to isotropic diffusion,
with the following parameters: TR/TE=2000/37 ms,
FOV=20620 mm
2, matrix size=128664, slice thick-
ness=0.5 mm, 25 slices, 2 averages, diffusion time=40 ms,
gradient pulse width=10 ms and b-values (diffusion weighting)
of 120 and 1200 s/mm
2. Total acquisition time was 8 minutes and
32 seconds. DW-MRI scans were discontinued following day 15
post-treatment initiation.
Image Reconstruction and Analysis
Volumes of interest (VOIs) were manually contoured along the
enhancing rim of the tumors on the contrast-enhanced T1-
weighted images for tumor volume measurements and determi-
nation of whole-tumor means of ADC. Tumor doubling times
were determined over the first week of treatment by linearizing
tumor volume measurements, calculating the slope (i.e. tumor
growth rate) using a linear regression algorithm and dividing ln(2)
to the rate. ADC maps were calculated from the two diffusion
weightings (b-values) using the following equation:
ADC~ln
S1
S2
 
b2{b1 ðÞ
where S1 and S2 are the signal intensities at b-values b1 and b2,
respectively, and ADC is the apparent diffusion coefficient
obtained using b1 and b2. Voxels that exhibit insufficient signal,
defined as ,10*noise, in the low b-value image (b=120 s/mm
2)
were excluded from the analysis. Subsequently, mean ADC values
were calculated over the tumor volume. All image reconstruction
and digital image analysis was accomplished using in-house
programs developed in Matlab (The Mathworks, Natick, MA,
USA).
Protein study
Tumor tissue from untreated or treated animals was extracted,
snap frozen and stored at 280 C. Lysis was performed using
standard lysis buffer (Ripa) by homogenizing the tumor tissue.
Western blotting for cleaved Caspase-3 was performed following
standard procedures and the following antibodies: Caspase-3 (Cell
Signaling), b-Actin (Abcam), Gapdh-HRP (Abcam).
Histology
For each of the treatments, four animals from each group were
sacrificed for histological analysis of the tumors at D2 and D7 (2
and 7 days after treatment initiation, respectively). Tissues were
fixed in formalin, transferred to ethanol and embedded in paraffin.
Tissue sections were stained with H&E (cell viability) and with
cleaved Caspase-3 antibody (Cell Signaling) after antigen retrieval
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(Vectastain, Vector labs, Burlingame, CA) and disclosed with DAB
Solution (Vector labs, Burlingame, CA).
Statistics
Treatment efficacy on overall survival was assessed by log-rank
test and displayed using Kaplan-Meier survival curves. Group
comparisons of percent change in tumor volume and mean ADC
were assessed at individual time points using a Analysis of
Variance (ANOVA). All statistical computations were performed
with a statistical software package (SPSS Software Products,
Chicago, IL). Statistical significance was assessed at p,0.05.
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